Vanda Pharmaceuticals appoints chief commercial officer

Bob Repella joins US biopharmaceutical firm

Vanda Pharmaceuticals has named Bob Repella as senior vice president and chief commercial officer of the US biopharmaceutical firm that specialises in clinical-stage products for CNS disorders.

Repella has more than 25 years of experience in the biotech/pharmaceutical industry, including senior-level leadership roles in global marketing, sales, new product development and commercial operations.

Prior to joining Vanda, he was senior vice president of Pharmaceutical Operations for the Americas at Cephalon.

Before this, Repella was executive vice president and general manager of the Biopharma Business Unit for Wyeth Pharmaceuticals.

Earlier in his career, Repella held positions with Johnson & Johnson's McNeil Pharmaceutical Division, Merck & Co and Eli Lilly.

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

Latest EU drug approvals span range of health issues

Cancer was again at the forefront of the NMEs reaching the market in 2015, but new drugs also benefited other disease areas. Dr Sarah Houlton looks at the latest therapeutic arrivals
Regulatory

Sleep disorders – tasimelteon

Melatonin can be used to treat sleep disorders, but it has poor bioavailability, and has a half-life in the body of only about 15 minutes
Manufacturing

CARBOGEN AMCIS introduces SPRINT for early-phase development

A new, phase-appropriate approach designed to accelerate early-phase progression while maintaining scientific rigour
Manufacturing

How the QA and QP talent market is changing in pharma

Recruiting and retaining experienced quality and regulatory professionals has become significantly more complex for pharmaceutical and biotech companies
Regulatory

Andelyn Biosciences strengthens CDMO credentials with full ICMC certification

The certification received by Andelyn underscores their long-standing commitment to quality, operational readiness, and client service as the company supports innovators in advancing gene therapies from development through clinical and commercial manufacturing
Regulatory

MHRA approves beremagene geperpavec gene therapy gel for DEB from birth

The MHRA has approved beremagene geperpavec (Vyjuvek), a topical gene therapy gel for wounds in patients with dystrophic epidermolysis bullosa (DEB), for use from birth onwards
Regulatory

FDA approves AstraZeneca's FASENRA for hypereosinophilic syndrome

AstraZeneca's FASENRA has received FDA approval for hypereosinophilic syndrome in adults and adolescents aged 12 and above, based on Phase III NATRON trial data showing a 65% reduction in the risk of first HES flare compared to placebo
Subscribe now